Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

Table 7 Sustained virologic response outcome by prognostic baseline factors in patients with genotypes 1, 3, and 6 hepatitis C virus infection

Comparison or stratum	OR (95%CI)	P value
Age	1.00 (0.96-1.04)	0.904
Genotype (1 vs 6)	0.74 (0.30-1.84)	0.433
Genotype (3 vs 6)	1.33 (0.58-3.05)	0.433
High pretreatment HCV RNA (≥ 800000 IU/mL)	0.42 (0.19-0.92)	0.029
High pretreatment albumin (≥ 3.5 g/dL)	2.63 (1.11-6.22)	0.028
High pretreatment platelet (≥ 150000/mm3)	1.00 (0.45-2.25)	0.992
Liver fibrosis (F3-4 vs F ≤ 2)	0.19 (0.08-0.48)	< 0.001
Sex (female vs male)	0.57 (0.28-1.16)	0.120
Treatment duration (48 wk vs 24 wk)1	2.05 (0.42-9.92)	0.371

¹Only in patients with genotype 3 HCV infection. HCV: Hepatitis C virus.